{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T01:17:25Z","timestamp":1773019045486,"version":"3.50.1"},"reference-count":32,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2024,5,12]],"date-time":"2024-05-12T00:00:00Z","timestamp":1715472000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Int J Dermatology"],"published-print":{"date-parts":[[2024,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Certolizumab is an Fc\u2010free PEGylated tumor necrosis factor\u2010alpha (TNF\u03b1) inhibitor recently approved for the treatment of moderate\u2010to\u2010severe plaque psoriasis, although there is limited real\u2010world evidence on the effectiveness and safety in patients with plaque psoriasis treated with certolizumab.<\/jats:p>\n                    <jats:p>The objective of this article is to determine the effectiveness, drug survival, and safety, including pregnancy, childbirth, and lactation, of certolizumab in moderate\u2010to\u2010severe plaque psoriasis under real\u2010world conditions.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This is a retrospective, multicenter, observational study performed in 15 hospitals in Spain. It evaluates the effectiveness and safety of certolizumab in plaque psoriasis in the clinical practice setting.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 67 patients (73% female) were evaluated with a mean baseline Psoriasis Area Severity Index (PASI) of 8.9. At Week 12, the mean PASI was 2.3 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200967), 1.3 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200957) at Week 24 and 1.3 at Week 52 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200934). Absolute PASI\u2009&lt;\u20093 was achieved in 69, 86, and 92% of patients at Weeks 12, 24, and 52, respectively, as observed. For its part, using the under\u2010response imputation analysis, PASI\u2009&lt;\u20093 at Weeks 12, 24, and 52 were achieved by 69, 73, and 49% of the patients, respectively. A total of 35 patients (52%) had concomitant psoriatic arthritis, and, in 24 of them, Disease Activity in Psoriatic Arthritis Score (DAPSA) was recorded at baseline, with a mean value of 17.9 which decreased to 8.2 at Week 12 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200922) and to 3.6 at Week 24 (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200918). Certolizumab treatment was discontinued in 14 out of 67 patients (21%), due to lack\/loss of cutaneous or articular effectiveness (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200911) or patient decision (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092) or adverse event in only one patient who developed active tuberculosis. A lower baseline PASI [hazard ratio (HR): 1.12 (1.02\u20131.23);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.023] and a more significant reduction in PASI at Week 12 [HR: 1.16 (1.07\u20131.27);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009&lt;\u20090.001] and Week 52 [HR: 1.47 (1.11\u20131.96);\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007] was shown to be significantly related with better survival for the entire follow\u2010up period. Fourteen patients were treated during pregnancy and\/or lactation without reporting adverse events in either the patient or the newborn.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Certolizumab consistently showed high effectiveness and drug survival rates in this real\u2010life cohort. The safety demonstrated in clinical trials during pregnancy and lactation seems to be confirmed in clinical practice.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ijd.17238","type":"journal-article","created":{"date-parts":[[2024,5,13]],"date-time":"2024-05-13T00:05:58Z","timestamp":1715558758000},"page":"1720-1727","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Certolizumab pegol effectiveness, survival and safety in patients with psoriasis: A multicenter retrospective analysis in daily clinical practice by the Spanish Psoriasis Group"],"prefix":"10.1111","volume":"63","author":[{"given":"Antonio","family":"Sahuquillo\u2010Torralba","sequence":"first","affiliation":[{"name":"Department of Dermatology Hospital Universitario y Polit\u00e9cnico La Fe, Instituto de Investigaci\u00f3n Sanitaria (IIS) La Fe  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6730-6723","authenticated-orcid":false,"given":"Miguel","family":"Mansilla\u2010Polo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario y Polit\u00e9cnico La Fe, Instituto de Investigaci\u00f3n Sanitaria (IIS) La Fe  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Conrad","family":"Pujol\u2010Marco","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario y Polit\u00e9cnico La Fe, Instituto de Investigaci\u00f3n Sanitaria (IIS) La Fe  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar","family":"Llamas\u2010Velasco","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario de la Princesa, Instituto de Investigaci\u00f3n Sanitaria La Princesa (IIS\u2010IP)  Madrid Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva V.","family":"Rull","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0381-6174","authenticated-orcid":false,"given":"Ricardo","family":"Ruiz Villaverde","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitario San Cecilio  Granada Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Ferran","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital del Mar\u2010Institut Mar d'Investigacions  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Pitarch","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General Universitario  Castell\u00f3n Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lopez","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de la Santa Creu i Sant Pau  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma","family":"Beltran","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Hospital del Mar  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Urruticoechea\u2010Arana","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Hospital de Can Misses  Ibiza Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep","family":"Riera\u2010Monroig","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Clinic de Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merce","family":"Alsina","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Clinic de Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Vidal","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital de Igualada  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6007-7320","authenticated-orcid":false,"given":"Isabel","family":"Belinch\u00f3n Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital General Universitario Dr. Balmis\u2010ISABIAL, Universidad Miguel Hern\u00e1ndez  Alicante Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jaime","family":"Notario","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari de Bellvitge, Hospitalet de Llobregat  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4266-0771","authenticated-orcid":false,"given":"Jos\u00e9 M.","family":"Carrascosa","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Germans Trias i Pujol, Badalona, Universidad Aut\u00f3noma de Barcelona  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0330-7599","authenticated-orcid":false,"given":"V\u00edctor","family":"Gonzalez\u2010Delgado","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Cl\u00ednico Universitario  Valencia Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jordi","family":"Mollet","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Vall d'Hebron  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miquel","family":"Ribera","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital Universitari Parc Taul\u00ed  Sabadell, Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernando","family":"Gallardo","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital del Mar\u2010Institut Mar d'Investigacions  Barcelona Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2024,5,12]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2007.08148.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.33415"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/keq105"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI200316069"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.2119\/2006-00003.Gulko"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2004.032268"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21306"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20335"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD011535.pub3"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2020-217159"},{"key":"e_1_2_7_12_1","unstructured":"European Medicines Agency (EMA).Cimzia summary of product characteristics. Available from:https:\/\/www.ema.europa.eu\/en\/documents\/product\u2010information\/cimzia\u2010epar\u2010product\u2010information_en.pdf."},{"key":"e_1_2_7_13_1","unstructured":"US Food and Drug administration (FDA).Cimzia prescribing information. Available from:https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125160s237lbl.pdf."},{"key":"e_1_2_7_14_1","unstructured":"Electronic medicines compendium.Cimzia. Available from:http:\/\/www.medicines.org.uk\/emc\/medicine\/32367."},{"key":"e_1_2_7_15_1","unstructured":"PorterC Armstrong\u2010FisherS KopotshaT SmithB BakerT KevorkianL et\u00a0al.Certolizumab pegol does not bind the neonatal Fc receptor (FcRn): consequences for FcRn\u2010mediated in vitro transcytosis and ex vivohuman placental transfer."},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-212196"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2017-211384"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.40508"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16684"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.19039"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.16606"},{"key":"e_1_2_7_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdcr.2018.06.003"},{"key":"e_1_2_7_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-017-0208-z"},{"key":"e_1_2_7_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2019.01.023"},{"key":"e_1_2_7_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ad.2018.02.010"},{"key":"e_1_2_7_26_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1605143"},{"key":"e_1_2_7_27_1","doi-asserted-by":"publisher","DOI":"10.1159\/000495655"},{"key":"e_1_2_7_28_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-019-0290-5"},{"key":"e_1_2_7_29_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.13409"},{"key":"e_1_2_7_30_1","doi-asserted-by":"publisher","DOI":"10.1111\/dth.14929"},{"key":"e_1_2_7_31_1","doi-asserted-by":"publisher","DOI":"10.1177\/12034754221078203"},{"key":"e_1_2_7_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jdin.2021.05.003"},{"key":"e_1_2_7_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2019.03.0"}],"container-title":["International Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17238","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/ijd.17238","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ijd.17238","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:23:00Z","timestamp":1773015780000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ijd.17238"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,12]]},"references-count":32,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,12]]}},"alternative-id":["10.1111\/ijd.17238"],"URL":"https:\/\/doi.org\/10.1111\/ijd.17238","archive":["Portico"],"relation":{},"ISSN":["0011-9059","1365-4632"],"issn-type":[{"value":"0011-9059","type":"print"},{"value":"1365-4632","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,5,12]]},"assertion":[{"value":"2024-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-04-24","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2024-05-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}